Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RGS12 | O14924 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795967 | 1.00 | KCNQ2 (0.38) | KCNQ2MAPTLMNAMEN1KMT2A | |
| SCHEMBL2437814 | 0.90 | MEN1 (0.43) | KCNQ2MAPTLMNAMEN1KMT2A | |
| SCHEMBL30794628 | 0.84 | MAPT (0.41) | KCNQ2MAPTLMNAMEN1KMT2A | |
| SCHEMBL2436625 | 0.84 | MAPT (0.41) | KCNQ2MAPTLMNAMEN1KMT2A | |
| SCHEMBL2437736 | 0.84 | MAPT (0.41) | KCNQ2MAPTLMNAMEN1KMT2A | |
| SCHEMBL30795849 | 0.84 | MAPT (0.41) | KCNQ2MAPTLMNAMEN1KMT2A | |
| SCHEMBL2436213 | 0.82 | GPR183 (0.39) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL30794937 | 0.81 | SIRT5 (0.41) | KCNQ2MAPTLMNAMEN1KMT2A | |
| SCHEMBL2437983 | 0.81 | SIRT5 (0.41) | KCNQ2MAPTLMNAMEN1KMT2A | |
| SCHEMBL2435159 | 0.80 | KCNQ2 (0.60) | KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299075-B2 | Substituted thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | claimed |
| US-20110294787-A1 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-12-01 | — | — | US | claimed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| EP-2138487-A1 | Substituted morpholine and thiomorpholine derivatives for the treatment of bipolar disorders | H. Lundbeck A/S (DK) | 2009-12-30 | — | — | EP | claimed |
| US-7632835-B2 | 2-Cyclopentyl-N-(2-bromo-6-trifluoromethyl-4-(thio)morpholin-4-yl-phenyl)-acetamide; potent openers of the KCNQ family of potassium ion channels; antiepileptic agents; anticonvulsants; anxiolytic agents; neurodegenerative disorders; analgesics for headaches, neuropathic pain; bipolar disorders | H. LUNDBECK A/S (DK) | 2009-12-15 | — | — | US | claimed |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| EP-1727809-B8 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2008-10-29 | — | — | EP | claimed |
| EP-1727809-B1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2008-06-11 | — | — | EP | claimed |
| EP-1727809-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H.Lundbeck A/S (DK) | 2006-12-06 | — | — | EP | claimed |
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | claimed |
| WO-2005087754-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-09-22 | — | — | WO | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
| EP-1727809-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H.Lundbeck A/S (DK) | 2006-12-06 | — | — | EP | disclosed |
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| WO-2005087754-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | OPRM1, OPRK1, OPRD1 | KCNQ2 512/4885MAPT 169/4885LMNA 4789/4885 |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRD1 | KCNQ2 521/4885MAPT 176/4885LMNA 4815/4885 |
| US-20110294787-A1 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRL1 | KCNQ2 1218/4885MAPT 359/4885LMNA 4865/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | KCNQ2 1/4885MAPT 1260/4885LMNA 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.